Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common cause of dementia accounting for about 60–80% of the cases. With the rise of population of elderly people all over the world, providing greater medical relief to the patients suffering from Alzheimer’s disease has become a matter of great urgency. The exact etiology of AD is still unexplained but several hypotheses explaining the pathophysiology of AD have been put forward.